Collegium Pharmaceutical (NASDAQ:COLL) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Friday.

According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. “

Several other research analysts have also recently weighed in on the stock. HC Wainwright restated a “buy” rating on shares of Collegium Pharmaceutical in a research report on Monday, September 17th. BidaskClub cut shares of Collegium Pharmaceutical from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 18th. Cantor Fitzgerald set a $35.00 price objective on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Friday, September 21st. Finally, Janney Montgomery Scott set a $27.00 price objective on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Monday, August 6th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $31.71.

COLL stock opened at $15.42 on Friday. The company has a current ratio of 0.82, a quick ratio of 0.78 and a debt-to-equity ratio of 3.94. The company has a market capitalization of $514.27 million, a P/E ratio of -6.24 and a beta of 0.24. Collegium Pharmaceutical has a 1-year low of $12.49 and a 1-year high of $29.90.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Thursday, November 8th. The specialty pharmaceutical company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.14). The company had revenue of $70.20 million during the quarter, compared to the consensus estimate of $74.79 million. Collegium Pharmaceutical had a negative return on equity of 61.82% and a negative net margin of 39.10%. The firm’s revenue for the quarter was up 485.0% on a year-over-year basis. During the same quarter last year, the company posted ($0.45) earnings per share. As a group, sell-side analysts predict that Collegium Pharmaceutical will post -1.53 earnings per share for the current year.

In other Collegium Pharmaceutical news, Director Michael Thomas Heffernan sold 25,000 shares of the stock in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $16.53, for a total transaction of $413,250.00. Following the transaction, the director now directly owns 361,000 shares in the company, valued at $5,967,330. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 25.76% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of COLL. Atria Investments LLC bought a new position in Collegium Pharmaceutical during the second quarter valued at approximately $201,000. Cubist Systematic Strategies LLC bought a new position in Collegium Pharmaceutical during the second quarter valued at approximately $213,000. State Board of Administration of Florida Retirement System grew its position in Collegium Pharmaceutical by 34.7% during the second quarter. State Board of Administration of Florida Retirement System now owns 13,704 shares of the specialty pharmaceutical company’s stock valued at $327,000 after acquiring an additional 3,530 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. bought a new position in Collegium Pharmaceutical during the second quarter valued at approximately $384,000. Finally, Monarch Partners Asset Management LLC grew its position in Collegium Pharmaceutical by 26.9% during the third quarter. Monarch Partners Asset Management LLC now owns 28,340 shares of the specialty pharmaceutical company’s stock valued at $418,000 after acquiring an additional 6,000 shares during the last quarter. Institutional investors and hedge funds own 94.41% of the company’s stock.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

See Also: How to Profit and Limit Losses With Stop Orders

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.